Physician profile
Joseph Cappa
NPI 1639273212
$200,203.68
in general payments reported to CMS, 2019-2025
40 companies · $35K in 2025
The $35K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $6,496 · 2021: $30K · 2022: $22K · 2023: $50K · 2024: $36K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $74K · Consulting Fee: $19K · Food and Beverage: $13K · Travel and Lodging: $12K · Honoraria: $2,670 · Debt Forgiveness: $479 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $73,671.15 |
| Consulting Fee | $19,362.50 |
| Food and Beverage | $12,510.17 |
| Travel and Lodging | $11,907.91 |
| Honoraria | $2,670.00 |
| Debt Forgiveness | $478.58 |
| Education | $142.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $66,660.55 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $42,483.61 | 2019-2023 | Zeposia |
| Janssen Scientific Affairs, LLC | $35,466.55 | 2019-2025 | Stelara, Tremfya |
| Pfizer INC. | $19,551.90 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10,073.95 | 2019-2025 | Entyvio, Gattex |
| Abbvie INC. | $6,356.26 | 2019-2025 | Skyrizi, Linzess, Rinvoq |
| Ferring Pharmaceuticals INC. | $4,514.59 | 2019-2021 | |
| Gastrogpo, LLC | $3,714.00 | 2023-2024 | |
| Celgene Corporation | $3,113.92 | 2021-2024 | Zeposia |
| Pharmacosmos Therapeutics INC. | $2,670.00 | 2024 | Monoferric |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,167.94 | 2019-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $606.30 | 2024-2025 | Omvoh |
| Olympus America INC. | $478.58 | 2023 | Evis Exera Lll Colonovideoscope |
| Phathom Pharmaceuticals, INC. | $397.89 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $355.38 | 2022-2025 | Dupixent |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Cappa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.